Tuesday September 24, 2019
Home India Shaw: India n...

Shaw: India needs to up its game in Science and Technology

0
//

Bengaluru: Biocon chairperson Kiran Mazumdar Shaw stated on Tuesday that India continues to be a sub-optimal country when it comes to investing in the science and technology sector.

Biocon Limited is an Indian bio-pharmaceutical company based in Bangalore, India headed by Indian entrepreneur Kiran Mazumdar Shaw. Shaw was awarded the Othmer Gold Medal for her outstanding contributions to the progress of science and chemistry in 2014.

“Amongst all the countries who invest in science and technology, we are at a sub-optimal level,” said Shaw at Bangalore India Bio.

Referring to South Korea, which is leading investments in science and technology, she said: “I think India needs to basically up its game in science and technology through greater investments.”

She requested the government to increase science and technology investments as it is the future of India.

According to the Biocon chairperson, India needs to invest $5 billion in biotechnology to achieve the target of growing the sector to $100 billion by 2025.

“Today biotechnology is a $11 billion sector, growing at a compounded annual growth rate of 20 percent. We also are aspiring to be a $100 billion sector by 2025,” she said.

Addressing the 16th edition of Bangalore India Bio, Union Science and Technology Minister Harsh Vardhan said: “A lot has been achieved in this field in the last 30 years. Bangalore is not only the hub of bio-tech, it is also the destination of all scientists in India. It is the science hub for India.”

He said the government allotted Rs 10,000 to support entrepreneurs and startups in biotechnology.

Scheduled from February 9-11, Bangalore India Bio will cover a spectrum of activities which include an international trade show, keynote talks and multi-track conferences among others.

As many as 25 sessions featuring 110 speakers will deliberate on topics like making tomorrow’s medicine, oncology and precision medicine, rare diseases and orphan drugs, agribiotechnology, synthetic bio-fuels and others. (IANS)

Next Story

Biocon to Make Three Generic Drugs for Hard-Selling in China

The 10-year agreement envisages Biocon to supply the products to CMS for selling in mainland China

0
Biocon, Drugs, China
We have signed an agreement with the subsidiary of China Medical System Holdings Ltd (CMS) to develop, manufacture and supply three generic drugs in the Chinese market. Pixabay

Biotechnology major Biocon would make three generic drugs for hard-selling in China through partnership, the company said on Saturday.

“We have signed an agreement with the subsidiary of China Medical System Holdings Ltd (CMS) to develop, manufacture and supply three generic drugs in the Chinese market,” the city-based firm said in a statement.

The 10-year agreement envisages Biocon to supply the products to CMS for selling in mainland China.

“The foray into China is a part of our long-term generic formulations strategy to expand our business in the Chinese pharmaceuticals market,” said the statement.

Biocon, Drugs, China
Biotechnology major Biocon would make three generic drugs for hard-selling in China through partnership, the company said on Saturday. Pixabay

As the world’s second largest pharma market, the addressable market size for the three drugs is about $800 million (Rs 5,680 crore), according to IQVIA, a US multinational firm that serves health IT and clinical research.

“The collaboration with CMS will allow us to take our US approved generic formulations to patients in China with an early entry,” said Biocon Chief Executive Arun Chandavarkar in the statement.

Also Read- Tiny Bubbles in Our Body might Potentially be Used to Treat Cancer

The company, however, did not specify the diseases which the three generic drugs will aim to treat. (IANS)